Discover
KLRS
Kalaris Therapeutics, Inc.
3.20
2 x 3.12
2 x 5.60
bid
ask
+
0.04
1.27%
2 @ 07:30 PM
3.20 +0.00 (0.00%)
| Ytd | -62.09% | |
| 1y | -27.11% |
3.04
day range
3.23
3.16
52 week range
10.98
| Open | 3.18 | Prev Close | 3.16 | Low | 3.04 | High | 3.23 | Mkt Cap | 76.18M |
| Vol | 234.40K | Avg Vol | 253.48K | EPS | -1.90 | P/E | N/A | Forward P/E | N/A |
| Beta | 0.22 | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 3.93 | 200-d Avg | 6.31 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 12.39M | ||
| Research and Development Expense | 9.02M | ||
| Selling, General and Administrative Expense | 3.37M | ||
| Operating Income | -12.39M | ||
| Net Income | -11.51M | ||
| Net Income Common Stock | -11.51M | ||
| Net Income Common Stock (USD) | -11.51M | ||
| Consolidated Income | -11.51M | ||
| Earnings per Basic Share | -0.48 | ||
| Earnings per Basic Share (USD) | -0.48 | ||
| Earnings per Diluted Share | -0.48 | ||
| Earning Before Interest & Taxes (EBIT) | -11.51M | ||
| Earning Before Interest & Taxes (USD) | -11.51M | ||
| Weighted Average Shares | 23.80M | ||
| Weighted Average Shares Diluted | 23.80M | ||
| Balance Sheet | |||
| Cash and Equivalents | 43.67M | ||
| Cash and Equivalents (USD) | 43.67M | ||
| Investments | 50.37M | ||
| Investments Current | 50.37M | ||
| Current Assets | 95.92M | ||
| Property, Plant & Equipment Net | 1.39M | ||
| Total Assets | 99.54M | ||
| Debt Current | 347.00K | ||
| Total Debt | 1.40M | ||
| Current Liabilities | 8.74M | ||
| Debt Non-Current | 1.05M | ||
| Total Liabilities | 41.87M | ||
| Accumulated Retained Earnings (Deficit) | -182.37M | ||
| Accumulated Other Comprehensive Income | -73.00K | ||
| Shareholders Equity | 57.67M | ||
| Shareholders Equity (USD) | 57.67M | ||
| Assets Non-Current | 3.62M | ||
| Total Debt (USD) | 1.40M | ||
| Liabilities Non-Current | 33.13M | ||
| Trade and Non-Trade Payables | 1.12M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 53.00K | ||
| Net Cash Flow from Financing | -377.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 8.75M | ||
| Issuance (Purchase) of Equity Shares | 10.00K | ||
| Net Cash Flow from Investing | 20.17M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 20.17M | ||
| Net Cash Flow from Operations | -11.05M | ||
| Share Based Compensation | 644.00K | ||